Levonordefrin
Carbocaine, Carbocaine W/ Neo-cobefrin, Ravocaine Novocain W/, Ravocaine Novocain W/ Neo-cobefrin (levonordefrin) is a small molecule pharmaceutical. Levonordefrin was first approved as Carbocaine w/ neo-cobefrin on 1982-01-01. It is used to treat oral ulcer and toothache in the USA. It is known to target alpha-1D adrenergic receptor.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Levonordefrin
+
Mepivacaine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CARBOCAINE W/ NEO-COBEFRIN | Eastman Kodak | N-012125 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Levonordefrin
+
Procaine hydrochloride
+
Propoxycaine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| RAVOCAINE AND NOVOCAIN W/ NEO-COBEFRIN | Eastman Kodak | N-008592 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Mepivacaine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CARBOCAINE | Eastman Kodak | N-012125 DISCN | 1982-01-01 | 1 products, RLD |
Hide discontinued
Norepinephrine bitartrate
+
Procaine hydrochloride
+
Propoxycaine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| RAVOCAINE AND NOVOCAIN W/ LEVOPHED | Eastman Kodak | N-008592 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| carbocaine | ANDA | 2021-07-08 |
| scandonest 2% l | ANDA | 2020-09-22 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| oral ulcer | HP_0000155 | D019226 | — |
| toothache | — | D014098 | K08.89 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
60 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | 1 | 5 | 10 | 7 | 1 | 23 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 1 | 9 | 3 | — | 13 |
| Chronic pain | D059350 | HP_0012532 | — | — | — | 2 | 1 | 3 | |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | — | — | 2 | — | 2 |
| Autism spectrum disorder | D000067877 | F84.0 | — | — | — | 1 | — | 1 | |
| Asperger syndrome | D020817 | EFO_0003757 | F84.5 | — | — | — | 1 | — | 1 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | — | — | 1 | — | 1 |
| Migraine without aura | D020326 | EFO_0005296 | G43.0 | — | — | — | 1 | — | 1 |
| Migraine with aura | D020325 | EFO_0005295 | G43.1 | — | — | — | 1 | — | 1 |
| Shoulder pain | D020069 | HP_0030834 | M25.51 | — | — | — | 1 | — | 1 |
Show 5 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | F33.9 | — | 1 | 3 | — | 1 | 4 | |
| Ischemic stroke | D000083242 | — | — | 1 | — | 1 | 2 | ||
| Vulvodynia | D056650 | N94.81 | — | — | 1 | — | — | 1 | |
| Back pain | D001416 | HP_0003418 | M54 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuralgia | D009437 | EFO_0009430 | — | 1 | — | — | — | 1 | |
| Irritable bowel syndrome | D043183 | EFO_0000555 | K58 | — | 1 | — | — | — | 1 |
| Low back pain | D017116 | HP_0003419 | M54.5 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tobacco use disorder | D014029 | F17 | — | — | — | — | 1 | 1 | |
| Post-lyme disease syndrome | D000077342 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | LEVONORDEFRIN |
| INN | corbadrine |
| Description | Alpha-methylnoradrenaline is a catecholamine in which the 2-aminoethyl group is substituted with a hydroxy group at C-1 and a methyl group at C-2, with configurations 1R,2S. A metabolite of alpha-methyl-L-dopa, it is an alpha2-adrenergic agonist and acts as a topical nasal decongestant and vasoconstrictor, most often used in dentistry. It has a role as an alpha-adrenergic agonist, a vasoconstrictor agent and a nasal decongestant. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C[C@H](N)[C@H](O)c1ccc(O)c(O)c1 |
Identifiers
| PDB | — |
| CAS-ID | 829-74-3 |
| RxCUI | 132889 |
| ChEMBL ID | CHEMBL677 |
| ChEBI ID | 10304 |
| PubChem CID | 164739 |
| DrugBank | DB06707 |
| UNII ID | V008L6478D (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
ADRA1D
ADRA1D
Organism
Homo sapiens
Gene name
ADRA1D
Gene synonyms
ADRA1A
NCBI Gene ID
Protein name
alpha-1D adrenergic receptor
Protein synonyms
adrenergic, alpha -1D-, receptor, adrenergic, alpha-1A-, receptor, Alpha-1A adrenergic receptor, Alpha-1D adrenoceptor, Alpha-1D adrenoreceptor, Alpha-adrenergic receptor 1a
Uniprot ID
Mouse ortholog
Adra1d (11550)
alpha-1D adrenergic receptor (P97714)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 412 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
811 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more